Merck (NYSE: MRK) recently released its Q4 results, with revenues and earnings exceeding the street estimates.

Merck’s full-year 2025 revenue guidance fell short of what some analysts were expecting, at a range of $64.1 billion to $65.6 billion.

GLP-1 receptor agonists were more cardioprotective in younger people, but reduced HbA1c more with age. The age of type 2 ...

MRK provided 2025 adjusted EPS guidance of $8.88 to $9.03, while the giant drugmaker expects sales of $64.1 billion to $65.6 ...

New GLP-1RA weight loss drugs like Like Ozempic and Wegovy have become extremely popular in recent months but researchers ...

Merck shares tumbled Tuesday morning after the drugmaker's soft outlook outweighed fourth-quarter revenue and adjusted profits topping expectations.

Merck's stock tumbled 11.8% Tuesday, putting it on track for its biggest one-day selloff in almost 17 years, after the drug company's softer-than-expected guidance amid struggles for its HPV vaccine ...

The week of Jan. 20, 2025, made history in a way few Americans realize. For the first time in 128 years, the Morbidity and ...

Those were partially offset by lower sales of diabetic medicines Januvia and Janumet, and lower combined sales of the human papillomavirus, or HPV, vaccine Gardasil/Gardasil 9, due to reduced ...

4Q23 results included charges related to the Daiichi Sankyo collaboration .

The S&P 500 added 0.7% on Tuesday, Feb. 4, as investors evaluated developments on U.S. tariffs, labor market data, and the latest earnings news.